Biogen Inc (BIIB US) , the partner of Samsung Biologics Co., Ltd (207940 KS) in the Samsung Bioepis JV, reported Q2 2017 results this morning and provided a strategic update. Biogen CEO Michel Vounatsos spoke positively about the JV (particularly the opportunity in Europe) and option. In fact, he said that it makes sense to exercise the option (expires at end of 2018, but the timing of exercise was not specified). We think that the main reason for this decision is the performance...(continued)

This insight is part of Smartkarma. For more follow this link.